International Lung Cancer Congress | Conference

4 Novel Drug Classes Demonstrate Early Promise for EGFR-Mutated NSCLC

July 31st 2021

Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.

Dr. Gandara on Incorporating MRD Testing into Lung Cancer Practice

July 31st 2021

David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.

Predicting the Future of Overcoming EGFR Resistance Mechanisms in NSCLC

July 31st 2021

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

Bispecifics Prove to Have Intriguing Role in Lung Cancer

July 30th 2021

Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.

Dr. Padda on Selecting a Therapy Following Osimertinib Resistance in NSCLC

July 30th 2021

Sukhmani K. Padda, MD, discusses treatment selection following osimertinib resistance in patients with non–small cell lung cancer.

Optimizing Osimertinib Treatment Strategies Relies on Identification of Resistance

July 30th 2021

Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor osimertinib in the first line setting are the key to unlocking the next wave of success in treating lung cancer.

Dr. Patel on the Potential With PARP/Immunotherapy Combos in NSCLC

July 30th 2021

Sandip P. Patel, MD, discusses the potential of combining PARP inhibitors with immunotherapy for patients with non–small cell lung cancer.

New Strategies for RET Inhibition May Expand Their Role in NSCLC

July 30th 2021

RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

Understanding the Role of the Pulmonologist in the Diagnosis and Management of Lung Cancer

July 29th 2021

Harmeet S. Bedi, MD, discusses the important role of pulmonologists in the diagnosis and management of patients with lung cancer.

MRD Offers a Potential Predictive Strategy to Further Personalize Treatment in NSCLC

July 29th 2021

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.

Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLC

July 27th 2020

Paul A. Bunn, Jr, MD, highlights encouraging data with fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Dr. Chiang on Unanswered Questions With Immunotherapy in NSCLC

July 27th 2020

Anne Chiang, MD, PhD, discusses unanswered questions with immunotherapy in non–small cell lung cancer.

Lara Shares Updates With Immunotherapy in Extensive-Stage SCLC

July 27th 2020

Although platinum-based chemotherapy given concurrently with a PD-L1 inhibitor has become the standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer, investigators have found that maintenance immunotherapy and combination strategies have fallen short of expectations.

Osimertinib Results Show Potential for Earlier TKI Use in EGFR-Mutant NSCLC

July 27th 2020

The introduction of tyrosine kinase inhibitor therapy earlier in the treatment timeline for patients with EGFR-mutant non–small cell lung cancer holds the promise of improving overall survival for this patient population.

Gandara Reflects on Current Status of TMB in NSCLC

July 27th 2020

David R. Gandara, MD, discusses the current state of tumor mutational burden in lung cancer, ongoing research further examining the utility of this biomarker, and challenges to address with future research.

Dr. Baas on the Promise of Immuno-Oncology in Mesothelioma

July 24th 2020

Paul Baas, MD, PhD, discusses recent updates in immuno-oncology within the field of mesothelioma.

Dr. Levy on the Efficacy of Crizotinib Versus Entrectinib in ROS1+ Lung Cancer

July 24th 2020

Benjamin P. Levy, MD, discusses the efficacy of crizotinib (Xalkori) versus entrectinib in ROS1-rearranged lung cancer.

Aggarwal Lends Insight on the Use of TKIs and Liquid Biopsies in ALK+ NSCLC

July 24th 2020

Charu Aggarwal, MD, MPH, discusses the current state of treatment for patients with ALK-positive non–small cell lung cancer, the utility of liquid biopsy, and remaining questions that need to be addressed in the space.

Bunn Breaks Down the Latest With Antibody-Drug Conjugates in Lung Cancer

July 24th 2020

Although antibody-drug conjugates have yet to receive regulatory approval in the lung cancer space, several emerging agents are showing early promise in clinical trials.

TRK Inhibitors Are a Safe, Effective Option in TRK Fusion-Positive Cancers

July 24th 2020

Clinical data shows that the TRK inhibitors entrectinib and larotrectinib induce high response rates with favorable toxicity profiles and central nervous system penetration, and are a viable treatment option for patients with advanced TRK fusion-positive cancers.